All @ investigational A/H@N@ vaccine formulations were well tolerated , and rapidly induced high antibody titers which met all of the Center for Biologics Evaluation and Research ( CBER ) and Committee for Medicinal Products for Human Use ( CHMP ) licensure criteria @ weeks after one dose .